The ORR of T-DXd as second-line therapy in patients with HER2-positive advanced gastric/GEJ adenocarcinoma was 42% (95% CI: 30.8–53.4). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.